What is cagrilintide?
Cagrilintide is an experimental once-a-week drug that switches on the amylin receptor. It has been studied mixed with semaglutide in a single shot called CagriSema, to get more weight loss than either drug alone. Amylin is a different appetite hormone from GLP-1, so the pair hits two different signals at once. This site's review found 3 studies in people covering more than 1,200 people. It is not FDA approved.
Studies in people from the compound pages this answer belongs to
- Cagrilintide
- Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial 2023 PMID 37364590
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial 2021 PMID 34798060
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2) 2025 PMID 40544432
Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.
Part of glp-1 and metabolic peptides. Semaglutide, tirzepatide, retatrutide, and the rest of the incretin and glucagon receptor family.